---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-027227"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:45:11.274845+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vir Biotech Q2 net loss $194.8M; hep B/delta data on track for Q4

## Summary
- Net loss $194.8M ($1.45/sh) vs $76.5M loss YoY; revenues $3.8M (incl $16.5M grant).
- Cash $1.9B at June 30; $273.6M paid to GSK for excess sotrovimab supply.
- Discontinued innate immunity small molecule platform to focus on antibody platform.
- Phase 2 PENINSULA flu trial (VIR-2482) missed primary and secondary endpoints.
- Phase 2 hep B/delta data (VIR-2218/VIR-3434) expected Q4 2023; HIV vaccine VIR-1388 Phase 1 dosing expected Q3.

## SEC filing metadata
- accession: 0001628280-23-027227
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828023027227/0001628280-23-027227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828023027227/vir-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-027227
- JSON: https://secwatch.observer/filing/0001628280-23-027227.json
- Plain text: https://secwatch.observer/filing/0001628280-23-027227.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.